Skip to Main Content
AI-generated illustration of a chrome robotic hand holding the chest piece of a stethoscope with red tubing on a walnut desk against a navy wall, representing AI tools from the 2026 Digital Health 50 entering Florida patient care.
Illustration created with AI image tools.

The 2026 Digital Health 50: A Florida Physician’s Guide

This week, CB Insights published its eighth annual Digital Health 50, a ranking of the private health technology companies its analysts consider most likely to succeed. The list is written for investors, but several of these companies already sit between Florida physicians and their patients. One reviews medication prior authorizations at AdventHealth. Another runs musculoskeletal and therapy utilization review for Humana. A third renews prescriptions in Utah without a physician signing most refills. Here is what the 2026 cohort does and what to ask before one of these tools touches your patients.

What the 2026 List Measures

CB Insights says its analysts chose 50 winners out of more than 50,000 digital health startups at the pre-seed to Series C stages, scoring them on deal activity, partnerships, investor strength, hiring momentum, revenue and the firm’s own predictive scores. The cohort has raised more than $3.5 billion in equity.

It is worth stating clearly that none of those measures is a patient outcome. A company can rank highly while its clinical evidence consists of internal data and press releases, so the list is best read as a map of where money and attention are going. According to HIT Consultant’s summary of the report, 26 of the 50 companies work on reducing administrative tasks such as insurance approvals and patient coordination, and that is where most physicians will feel the effect first.

AI Is Already in Your Prior Authorizations

Latent automates prior authorizations and appeals for specialty drugs by reading the chart and matching it against payer criteria. Becker’s reported that Cleveland Clinic, AdventHealth and five other systems were going live on its platform in 2026, bringing Latent to roughly 60 health systems. If you refer patients for infusions or specialty pharmacy through AdventHealth, an AI system may now be assembling the clinical justification the payer sees.

On the payer side, Cohere Health has handled prior authorization review for Humana since 2020, starting with musculoskeletal care and later adding cardiovascular and surgical services. Cohere states that 85% of authorizations on its platform are approved in real time and that the rest are reviewed by a clinician before a final determination. Humana has a large Medicare Advantage membership in Florida, so many orthopedic, cardiology and therapy requests from Florida practices pass through an algorithm before a human looks at them.

Florida law does not require insurers to say whether AI played a part in a denial. HB 527, which would have required a named, qualified human professional to make every claim denial, passed the House 108 to 0 in March and then died in the Senate Rules Committee. I have written before about how to fight prior authorization denials in Florida, and the same tactics apply when the first reviewer is software.

AI That Renews Prescriptions

Doctronic most directly tests where physician judgment ends. Under a regulatory sandbox agreement with Utah, its system renews prescriptions for chronic conditions after physicians review its first 250 renewals in each drug class. A JAMA Health Forum analysis described a formulary of 192 drugs for conditions such as hypertension, diabetes and depression. In the first five months, according to Fierce Healthcare, the AI recommended renewal in 72% of cases and reviewing physicians agreed 91% of the time. Those figures are company-reported and the sample is small.

The case for this program deserves to be made in full. Refill gaps are a real cause of uncontrolled blood pressure and glucose, patients wait days for portal replies, and a $4 renewal for a stable patient on lisinopril costs less than the visit it replaces. Supporters argue that physicians already approve most of these requests after a glance at the last lab value, and that a system with escalation rules may be more consistent than a tired clinician at the end of a clinic day. The opposing case is just as serious. A 91% agreement rate means physicians disagreed with roughly one recommendation in eleven, the data have not been independently audited, and no court has decided who carries liability when an autonomous renewal harms a patient. Both positions can hold at once: narrow, low-risk renewals may suit supervised automation, provided physicians write the protocol, review the escalations and see the audit data. For Florida physicians already facing the DEA telehealth prescribing deadline on December 31, this is the next question coming.

Chronic and Specialty Care Between Visits

The third theme is specialty care that continues between appointments, driven largely by Medicare’s ACCESS model, a 10-year voluntary CMS Innovation Center model that pays participating organizations for outcomes in technology-supported chronic care. The second cohort begins January 1, 2027, and CMS announced in September that heart failure, COPD, substance use disorder and tobacco cessation tracks will be added April 1, 2027. Cadence, which runs clinician-supervised remote monitoring with nearly 30 health systems, reports that a study in Mayo Clinic Proceedings: Innovations, Quality & Outcomes associated its program with 27% fewer hospital admissions and $1,302 lower annual cost per Medicare patient. That is observational data and should be read as an association.

Other winners build teams around the physician rather than replacing the visit. Chamber supports cardiologists managing heart failure under value-based contracts, and Salvo Health places dietitians, therapists and nurses inside community gastroenterology practices. BrainCheck offers an FDA Class II digital cognitive assessment used by more than 500 healthcare organizations. A repeatable baseline is useful, but a screening score is not a diagnosis, and the workup in our guide to memory complaints in the Florida exam room still applies.

What Florida Physicians Should Ask

  1. Ask your hospital which AI tools touch your orders. Medical staff leaders can request a list of AI systems used for prior authorization, medication access and patient outreach, and who reviews their output. The AI officers now joining Florida hospital leadership are the right people to ask.
  2. Request a human name on every adverse determination. When a Medicare Advantage request is denied, ask for the reviewing clinician’s name and credentials and a peer-to-peer discussion, since Florida law does not require plans to volunteer it.
  3. Check the evidence before you adopt a tool. Ask whether it has FDA clearance for your intended use, whether its outcome claims come from a randomized trial or company data, and whether the vendor will sign a business associate agreement. If it records encounters, review Florida’s consent rules for AI scribes first.
  4. Find out who manages your patients under ACCESS. If a participant enrolls your traditional Medicare patients, ask how it will report back to you and how medication changes will be coordinated.
  5. Bring this to your county medical society. The 2027 session convenes March 2, and lawmakers hear most clearly from organized medicine on whether AI-assisted denials should carry a named human reviewer.

The Bigger Picture

These companies are betting that much of the work around a physician’s decision can be automated, from the authorization request to the refill to the follow-up call. Some of it should be. What matters is who writes the rules. When physicians write the protocols and see the outcome data, these tools can give time back to patient care. When vendors and payers write them alone, physicians end up answering for decisions they never made.

Frequently Asked Questions

What is the CB Insights Digital Health 50?

It is an annual ranking of 50 private digital health startups, from pre-seed to Series C, that CB Insights considers most promising. The 2026 edition was published in mid-November 2026 in partnership with HLTH, and it is based on financial and commercial signals rather than clinical outcomes.

Are any Digital Health 50 companies working with Florida health systems?

Yes. Latent added AdventHealth to its medication access platform in 2026, and Cohere Health runs prior authorization review for Humana, which has a large Medicare Advantage membership in Florida. Other companies may be in use locally without public announcements.

Does Florida law require a human to review an AI-assisted insurance denial?

Not at present. HB 527 would have required a qualified human professional to make every claim denial, but it died in the Senate Rules Committee in March 2026 after passing the House unanimously. Physicians can still request the reviewer’s identity and a peer-to-peer discussion.

Can AI renew prescriptions in Florida?

The autonomous renewal program run by Doctronic operates under a Utah regulatory sandbox and is limited to patients located in Utah. Florida physicians should watch for similar proposals and for how liability is assigned if one appears.

What is the CMS ACCESS model?

ACCESS is a voluntary 10-year Medicare model that pays participating organizations based on outcomes for technology-supported chronic care in traditional Medicare. The second cohort starts January 1, 2027, and CMS plans to add heart failure, COPD, substance use disorder and tobacco cessation tracks on April 1, 2027.

This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Sean C. Orr, M.D., who holds full editorial responsibility for its content. Illustration created with AI image tools.

References

  1. CB Insights, “Digital Health 50: The most promising digital health startups of 2026” (November 2026). cbinsights.com
  2. HIT Consultant, “CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine” (November 17, 2026). hitconsultant.net
  3. Becker’s Hospital Review, “Cleveland Clinic, AdventHealth among 7 new Latent partners as pharmacy AI agents launch” (2026). beckershospitalreview.com
  4. Cohere Health, “How Humana Transformed Prior Authorization to Improve Care & Collaboration” (June 5, 2025). coherehealth.com
  5. Cohere Health, company home page (real-time approval figures). coherehealth.com
  6. The Florida Senate, CS/CS/HB 527 (2026), Mandatory Human Reviews of Insurance Claim Denials, bill history. flsenate.gov
  7. The Florida Senate, SB 202 (2026), Mandatory Human Reviews of Insurance Claim Denials, bill history. flsenate.gov
  8. Centers for Medicare & Medicaid Services, “CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F).” cms.gov
  9. Stanford Law School / JAMA Health Forum, “Utah’s Experiment With AI-Driven Prescription Renewals” (March 19, 2026). law.stanford.edu
  10. Fierce Healthcare, “Inside Doctronic’s AI prescription refill pilot program in Utah” (2026). fiercehealthcare.com
  11. Medical Economics, “Utah lets AI refill chronic prescriptions in state-backed pilot program” (January 8, 2026). medicaleconomics.com
  12. Centers for Medicare & Medicaid Services, “ACCESS Technical Frequently Asked Questions.” cms.gov
  13. First Coast Service Options, “How do I enroll in Medicare so I can participate in ACCESS?” medicare.fcso.com
  14. McDonald Hopkins, “CMS to expand ACCESS Model” (September 2026). mcdonaldhopkins.com
  15. Cadence, “Cadence named to the 2026 CB Insights’ 50 Most Promising Digital Health Startups” (November 16, 2026). cadence.care
  16. BrainCheck, “BrainCheck Raises $13 Million to Expand AI-Enabled Cognitive Care Platform,” Business Wire (February 2026). businesswire.com